Reinitiating Aspirin Therapy for Primary Prevention of Cardiovascular Events in a Patient Post-Aspirin-Induced Upper Gastrointestinal Bleed: A Case Report and Review of Literature

被引:3
|
作者
Adly, Gounathan [1 ]
Plakogiannis, Roda [2 ]
机构
[1] St Francis Hosp, Ctr Heart, Roslyn, NY USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA
关键词
LOW-DOSE ASPIRIN; RANDOMIZED-TRIAL; CORONARY CALCIUM; HEART-DISEASE; RISK; ULCER; CLOPIDOGREL; INFERIOR;
D O I
10.1345/aph.1R570
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe a case of continued aspirin use for primary prevention of a cardiovascular event in a patient post-aspirin-induced upper gastrointestinal (GI) bleed and evaluate published evidence to determine whether reinitiating aspirin therapy for this patient was appropriate. CASE SUMMARY: A 65-year-old man had been taking chronic low-dose (81 mg/day) aspirin therapy since 2002 for primary prevention of a cardiovascular event. He developed an upper GI bleed with lowered hemoglobin (9 mg/dL) and hematocrit (26.3%) after concomitantly taking 2 doses of naproxen (220 mg each). An objective causality assessment with the Naranjo probability scale revealed a probable adverse reaction of an upper GI bleed associated with concomitant naproxen and aspirin use. No further naproxen was taken. Aspirin was discontinued and pantoprazole was started, with resolution of the bleeding. Aspirin was restarted 2.5 months after pantoprazole was initiated, and no further bleeding occurred. DISCUSSION: Upper GI bleeds associated with aspirin therapy are well described in the literature. The management of cardiovascular event prophylaxis after a GI bleed is often controversial; consensus in regard to the optimal method of management does not exist. We evaluated GI protection strategies for patients with a history of aspirin-induced GI bleeding requiring cardiovascular prophylaxis. We found that the benefit of aspirin for the primary prevention of cardiovascular events needs to be carefully balanced with the risks associated with its use. The current literature supports that the best approach to prevent recurrent aspirin-induced GI bleeding is to administer a proton pump inhibitor with aspirin therapy. CONCLUSIONS: The benefit of aspirin for primary prevention of cardiovascular events needs to be carefully balanced with the risks associated with its use. Based on the current literature, the best approach to preventing recurrent aspirin-induced GI bleeds is to administer a proton pump inhibitor concomitantly with aspirin therapy.
引用
收藏
页数:5
相关论文
共 13 条
  • [1] Aspirin for the Primary Prevention of Cardiovascular Disease A Review of the Literature and Considerations for Clinical Practice
    Cicci, Jonathan D.
    Iyer, Prashanth
    Clarke, Megan M.
    Mazzella, Anthony J.
    CARDIOLOGY IN REVIEW, 2020, 28 (02) : 98 - 106
  • [2] Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the US Preventive Services Task Force
    Guirguis-Blake, Janelle M.
    Evans, Corinne V.
    Senger, Caitlyn A.
    O'Connor, Elizabeth A.
    Whitlock, Evelyn P.
    ANNALS OF INTERNAL MEDICINE, 2016, 164 (12) : 804 - U62
  • [3] Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review
    De Caterina, Raffaele
    Aimo, Alberto
    Ridker, Paul M.
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 199 - 206
  • [4] A review and study of aspirin utilization for the primary prevention of cardiovascular events in a psychiatric population
    Victor, Kaitlyn
    Skelly, Megan
    Mulcahy, Kimberly
    Demler, Tammie Lee
    Trigoboff, Eileen
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2018, 33 (05) : 274 - 281
  • [5] Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events A Systematic Review and Meta-analysis
    Zheng, Sean L.
    Roddick, Alistair J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (03): : 277 - 287
  • [6] Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit-A Systematic Review and Meta-Analysis
    Christiansen, Mikael
    Grove, Erik Lerkevang
    Hvas, Anne-Mette
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (05) : 478 - 489
  • [7] Low-Dose Aspirin and Upper Gastrointestinal Bleeding in Primary Versus Secondary Cardiovascular Prevention A Population-Based, Nested Case-Control Study
    Lin, Kueiyu Joshua
    De Caterina, Raffaele
    Garcia Rodriguez, Luis A.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (01): : 70 - 77
  • [8] Aspirin for the Primary Prevention of Cardiovascular Events A systematic review and meta-analysis comparing patients with and without diabetes
    Calvin, Andrew D.
    Aggarwal, Niti R.
    Murad, Mohammad Hassan
    Shi, Qian
    Elamin, Mohamed B.
    Geske, Jeffrey B.
    Fernandez-Balsells, M. Merce
    Albuquerque, Felipe N.
    Lampropulos, Julianna F.
    Erwin, Patricia J.
    Smith, Steven A.
    Montori, Victor M.
    DIABETES CARE, 2009, 32 (12) : 2300 - 2306
  • [9] Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Liu, Shuangbo
    Eckstein, Janine
    Lam, Anna
    Cheema, Asim N.
    CURRENT VASCULAR PHARMACOLOGY, 2023, 21 (02) : 111 - 119
  • [10] Ventricular fibrillation and sudden cardiac death induced by upper gastrointestinal bleeding in a patient receiving PCI: a case report and literature review
    Han, Dan
    Qiang, Hua
    Liu, Yingying
    Sun, Chaofeng
    Li, Guoliang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (09): : 13874 - 13880